Pharmaceuticals - Italy

  • Italy
  • In 2024, the revenue in the Pharmaceuticals market in Italy is projected to reach US$17.13bn.
  • The largest market within the pharmaceuticals industry is Oncology Drugs, with a projected market volume of US$3.03bn in 2024.
  • It is expected that the revenue will experience an annual growth rate of 4.00% from 2024 to 2029, resulting in a market volume of US$20.84bn by 2029.
  • When compared globally, United States is expected to generate the highest revenue, reaching US$630.30bn in 2024.
  • Italy's pharmaceutical market is thriving, driven by a strong focus on research and development, advanced healthcare infrastructure, and a growing aging population.

Key regions: United States, China, Germany, Japan, Europe

 
Market
 
Region
 
Region comparison
 
Currency
 

Analyst Opinion

Italy, known for its rich history, culture and cuisine, is also a significant player in the global pharmaceuticals industry.

Customer preferences:
The Italian population has a high demand for pharmaceutical products, with a focus on prescription drugs. The aging population in Italy has resulted in an increase in demand for drugs that treat chronic diseases such as hypertension, diabetes, and cardiovascular diseases. Additionally, there is a growing trend towards natural and herbal remedies, as Italians are becoming more conscious of their health and wellness.

Trends in the market:
The Italian pharmaceuticals market has been experiencing steady growth in recent years, driven by the increasing demand for prescription drugs and the growing trend towards natural and herbal remedies. The market is highly competitive, with both domestic and international players vying for market share. In recent years, there has been a trend towards consolidation, with larger companies acquiring smaller ones to expand their product portfolios and increase their market share.

Local special circumstances:
One unique aspect of the Italian pharmaceuticals market is the role of the National Health Service (NHS) in regulating drug prices. The NHS negotiates prices with pharmaceutical companies, which can result in lower prices for consumers. However, this can also lead to a slower uptake of new drugs, as companies may be hesitant to launch products in Italy due to the lower prices they can command.

Underlying macroeconomic factors:
The Italian pharmaceuticals market is influenced by a variety of macroeconomic factors, including government policies, healthcare spending, and the overall state of the economy. With Italy facing economic challenges in recent years, there has been pressure to reduce healthcare spending, which can impact the pharmaceuticals market. Additionally, changes in government policies, such as drug pricing regulations, can impact the profitability of pharmaceutical companies operating in Italy.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

Overview

  • Revenue
  • Analyst Opinion
  • Next generation therapy
  • Global Comparison
  • Methodology
  • Key Market Indicators
Please wait

Contact

Get in touch with us. We are happy to help.
Statista Locations
Contact Meredith Alda
Meredith Alda
Sales Manager– Contact (United States)

Mon - Fri, 9am - 6pm (EST)

Contact Yolanda Mega
Yolanda Mega
Operations Manager– Contact (Asia)

Mon - Fri, 9am - 5pm (SGT)

Contact Ayana Mizuno
Ayana Mizuno
Junior Business Development Manager– Contact (Asia)

Mon - Fri, 10:00am - 6:00pm (JST)

Contact Lodovica Biagi
Lodovica Biagi
Director of Operations– Contact (Europe)

Mon - Fri, 9:30am - 5pm (GMT)

Contact Carolina Dulin
Carolina Dulin
Group Director - LATAM– Contact (Latin America)

Mon - Fri, 9am - 6pm (EST)